Recombinant Mouse CD40 Ligand/TNFSF5 protein (His tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg0990
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <1.0 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse CD40 Ligand/TNFSF5 protein Gly115-Leu260 (Accession# P27548) with a His tag at the N-terminus. |
| GeneID | 21947 |
| Accession | P27548 |
| PredictedSize | 17.1 kDa |
| SDS-PAGE | |
| Formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
The CD40 ligand (CD40L, TRAP, CD154), a member of the TNF superfamily of ligands, is expressed as either a 33-kd transmembrane homologue or 18-kd soluble form (sCD154). CD40L is primarily expressed on activated CD4+ T cells and on a small proportion of CD8+ T cells and platelets. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. It has been suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. The CD40/CD40L system is also involved in tumorigenesis. Its expression is tightly regulated, and abnormal levels of CD40L are associated with the pathogenesis of atheromatous plaque destabilization and thrombotic events. Multiple mutations in CD40LG gene have been identified that are associated with hyper-IgM immunodeficiency syndrome type 1.
References:
1.Mazzei, G J et al. The Journal of biological chemistry vol. 270,13 (1995): 7025-8. 2.Zhang, Bikui et al. Immunology letters vol. 153,1-2 (2013): 58-61. 3.Rizvi, Muhammad et al. Trends in molecular medicine vol. 14,12 (2008): 530-8.